Market Place
Sourcing Support
BeyondSpring Presents Phase 2 Efficacy of Pembrolizumab Combo
11 Nov 2024 //
GLOBENEWSWIRE
BeyondSpring Presents DUBLIN-3 Data At ESMO 2024
16 Sep 2024 //
GLOBENEWSWIRE
BeyondSpring Presents NSCLC Study Results At ESMO 2024
16 Sep 2024 //
GLOBENEWSWIRE
BeyondSpring Presents Plinabulin Phase 3 Data At ISLAC 2024
10 Sep 2024 //
GLOBENEWSWIRE
BeyondSpring Presents Plinabulin Data at Lung Cancer Conference and ESMO 2024
03 Sep 2024 //
GLOBENEWSWIRE
BeyondSpring Files 2023 Annual Report on Form 20-F
29 Apr 2024 //
GLOBENEWSWIRE
BeyondSpring Business Update, Year End 2023 Financials
29 Apr 2024 //
GLOBENEWSWIRE
BeyondSpring Announces 1st Patient Dosed Pembrolizumab,Plinabulin Plus Etoposide
25 Mar 2024 //
GLOBENEWSWIRE
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price
26 Feb 2024 //
GLOBENEWSWIRE
BeyondSpring Receives Delinquency Notice Regarding Late Filing of Form 6-K
10 Jan 2024 //
GLOBENEWSWIRE
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
18 Dec 2023 //
GLOBENEWSWIRE
BeyondSpring Presents Poster Showing Immunomodulating Activity of Plinabulin
07 Nov 2023 //
GLOBENEWSWIRE
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Requirement
30 Oct 2023 //
GLOBENEWSWIRE
SEED Therapeutics Appoints Mr. Ko-Yung Tung to the Board of Directors
23 Oct 2023 //
GLOBENEWSWIRE
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
04 Oct 2023 //
GLOBENEWSWIRE
BeyondSpring and Leading Cancer Center to Present Poster at SITC™s 38th Meeting
27 Sep 2023 //
GLOBENEWSWIRE
BeyondSpring to Participate in R.W. Baird™s 2023 Global Healthcare Conference
07 Sep 2023 //
GLOBENEWSWIRE
SEED Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to BOD
20 Jun 2023 //
GLOBENEWSWIRE
BeyondSpring and Leading Cancer Center Present Highlighting Plinabulin Ability
07 Jun 2023 //
GLOBENEWSWIRE
BeyondSpring and Cancer Center to Present Poster at 2023 ASCO Annual Meeting
18 May 2023 //
GLOBENEWSWIRE
BeyondSpring Files 2022 Annual Report on Form 20-F
18 Apr 2023 //
GLOBENEWSWIRE
BeyondSpring Provides Business Update and Reports Year End 2022FYR
18 Apr 2023 //
GLOBENEWSWIRE
BeyondSpring Enrolls First Patient in Ph2 Study Plinabulin, Keytruda & Docetaxel
01 Mar 2023 //
GLOBENEWSWIRE
BeyondSpring Receives Notifications from Nasdaq Regarding Compliance
09 Jan 2023 //
GLOBENEWSWIRE
BeyondSpring Presents Data with Plinabulin for Docetaxel-Induced Neutropenia
13 Dec 2022 //
GLOBENEWSWIRE
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
23 Nov 2022 //
GLOBENEWSWIRE
BeyondSpring Presents New Clinical Evidence Plinabulin Protection of Granulocyte
13 Sep 2022 //
GLOBENEWSWIRE
BeyondSpring Presents New Data for the Use of Plinabulin and Pegfilgrastim
29 Aug 2022 //
GLOBENEWSWIRE
BeyondSpring Presents New Data in Chemotherapy-Induced Neutropenia and NSCLC
27 May 2022 //
GLOBENEWSWIRE
BeyondSpring Announces Three Poster Presentations at the ASCO
28 Apr 2022 //
GLOBENEWSWIRE
BeyondSpring Announces Q4 and Year End 2021 Financial Results
14 Apr 2022 //
GLOBENEWSWIRE
BeyondSpring Files 2021 Annual Report on Form 20-F
14 Apr 2022 //
GLOBENEWSWIRE
BeyondSpring to Announce Q4 and Year End 2021 Financial Results
08 Apr 2022 //
GLOBENEWSWIRE
BeyondSpring axes 35% of US staff after November drug rejection
13 Jan 2022 //
FIERCEBIOTECH
BeyondSpring Announces Third Quarter 2021 Financial Results
30 Dec 2021 //
GLOBENEWSWIRE
BeyondSpring Pharmaceuticals Announces Analysis of New Data on the Plinabulin
10 Dec 2021 //
GLOBENEWSWIRE
BeyondSpring lurches down as FDA rejects plinabulin
04 Dec 2021 //
FIERCEBIOTECH
BeyondSpring Announces First Patient Treated in Phase 2 Study with Plinabulin
21 Oct 2021 //
PRESS RELEASE
BeyondSpring Pharma Announces New Patient-Derived Model Data for Plinabulin
20 Oct 2021 //
GLOBENEWSWIRE
Matinas, Dynavax top weekly healthcare gainers; InnovAge, BeyondSpring trail
24 Sep 2021 //
SEEKINGALPHA
BeyondSpring Pharma Announces Positive Final Phase 3 DUBLIN-3 Data at ESMO21
20 Sep 2021 //
GLOBENEWSWIRE
BeyondSpring drops 16% despite `positive` plinabulin/docetaxel combo data
20 Sep 2021 //
SEEKINGALPHA
Is a Beyondspring drug helping lung cancer patients live longer?: Study
20 Sep 2021 //
STAT NEWS
BeyondSpring Pharmaceuticals Announces New Positive Data on Plinabulin
16 Sep 2021 //
GLOBENEWSWIRE
BeyondSpring Announces Second Quarter 2021 Financial Results
10 Sep 2021 //
GLOBENEWSWIRE
BeyondSpring gains as Baird sees FDA approval for its lead asset
08 Sep 2021 //
SEEKING ALPHA
BeyondSpring sheds over 10% recording second biggest loss for the year
07 Sep 2021 //
SEEKINGALPHA
BeyondSpring nails a $200M China deal in wake of a pivotal success
27 Aug 2021 //
ENDPTS
ICER to Assess Novel Agents to Prevent Chemotherapy-Induced Neutropenia
25 Aug 2021 //
ICER
BeyondSpring Strengthens Board with Commercial Head Brendan Delaney
14 Jul 2021 //
GLOBENEWSWIRE
BeyondSpring to Participate in the William Blair Biotech Focus Conference
08 Jul 2021 //
GLOBENEWSWIRE
BeyondSpring to Host R&D Day to Discuss Immune Agent Plinabulin in Anti-cancer
17 Jun 2021 //
GLOBENEWSWIRE
BeyondSpring Announces Q1 2021 Financial Results and Provides a Corporate Update
16 Jun 2021 //
GLOBENEWSWIRE
BeyondSpring Announces Final Positive Data from the CIN Program of Plinabulin
10 Jun 2021 //
GLOBENEWSWIRE
BeyondSpring Announces a Presentation of PROTECTIVE-2 Phase 3 Data
08 Jun 2021 //
GLOBENEWSWIRE
BeyondSpring Announces Positive Data from Ph3 Program of Plinabulin
07 Jun 2021 //
PRESS RELEASE
BeyondSpring Announces Submission of New Drug Application to U.S. FDA
01 Apr 2021 //
GLOBENEWSWIRE
BeyondSpring seeks US FDA & China NMPA’s nod for use of plinabulin
01 Apr 2021 //
PHARMABIZ
BeyondSpring Announces New Positive PROTECTIVE-2 Phase 3 Registrational Trial
10 Dec 2020 //
GLOBENEWSWIRE
